Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

News|Videos|October 3, 2023

EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

Author(s)Benjamin M. Brucker, MD, Eman A. Elkadry, MD, Jenna K. Horton, NP

Panelists identify key goals of therapy when treating OAB and identify resources that may aid in patient education.

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

Episodes in this series

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

Experts on OAB

EP. 2 EP. 1: An Introduction of the Speakers

Expert on OAB

EP. 3 EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

Expert on OAB

EP. 4 EP. 3: The Typical Patient with OAB and Common Signs and Symptoms

Expert on OAB

EP. 5 EP. 4: The Role of Urodynamic Testing in OAB Evaluation

Experts on OAB

EP. 6 EP. 5: OAB Treatment: Available Strategies and Rationale for Use

Expert on OAB

EP. 7 EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB

Expert on OAB

EP. 8 Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

Expert on OAB

EP. 9 EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB

Experts on OAB

EP. 10 EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

Expert on OAB

EP. 11 EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

Expert on OAB

EP. 12 EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies

Expert on OAB

EP. 13 EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting

Experts on OAB

EP. 14 EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

Expert on OAB

EP. 15 EP. 14: SNM and PTNS for OAB: Device Management and Followup

Expert on OAB

EP. 16 EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

FDA clears Revi Extend implant for urgency urinary incontinence

ByHannah Clarke

August 5th 2026

Sender Herschorn, BSc, MDCM, FRCSC, on vibegron efficacy in older men with OAB and BPH

BySender Herschorn, BSc, MDCM, FRCSC

July 8th 2026

Retrospective study suggests differences in OAB therapy persistence among older adults

ByUnwanaobong Nseyo, MD, MHS

June 20th 2026

Keith Xavier, MD, highlights UUI outcomes with ITNM across care settings

ByKeith Xavier, MD, URPS

May 27th 2026

Implantable tibial nerve stimulation outperforms sham in INTIBIA Pivotal Trial

ByCatherine A. Matthews, MD, FACOG, FACS, FPMRS

May 17th 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA clears Revi Extend implant for urgency urinary incontinence

Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma

Alan Bryce, MD, highlights key phase 3 advances in prostate cancer

FDA updates in urology: July 2026

FDA grants tentative approval to new cabozantinib capsule formulation